GlassScriptPhysician profile
Tommy K Ko
NPI 1881665081
$6,841.18
in general payments reported to CMS, 2019-2025
41 companies · $639 in 2025
The $639 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,228 · 2020: $736 · 2021: $988 · 2022: $1,491 · 2023: $1,408 · 2024: $353 · 2025: $639.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,399.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,399.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,072.03 | 2019-2025 | Fasenra, Breztri, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $756.54 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $625.36 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $590.79 | 2022-2025 | Dupixent |
| Grifols USA, LLC | $382.45 | 2019-2025 | Prolastin-C Liquid |
| Actelion Pharmaceuticals US, INC. | $362.89 | 2021-2023 | Uptravi, Opsumit |
| Mallinckrodt Hospital Products INC. | $259.89 | 2021-2023 | Acthar |
| Jazz Pharmaceuticals INC. | $258.96 | 2019-2023 | Xywav |
| Electromed, INC. | $229.55 | 2021-2025 | Smartvest |
| Genzyme Corporation | $216.86 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $205.97 | 2019-2023 | Dificid, Belsomra, Zerbaxa |
| Genentech USA, INC. | $180.73 | 2019-2023 | Xolair |
| Insmed, INC. | $180.63 | 2020-2025 | Arikayce, Brinsupri |
| Sunovion Pharmaceuticals INC. | $180.45 | 2019-2021 | |
| Abbvie INC. | $163.31 | 2021-2023 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $126.41 | 2020-2023 | |
| Teva Pharmaceuticals USA, INC. | $124.88 | 2019-2023 | Austedo Xr |
| Advanced Respiratory, INC | $117.19 | 2019-2021 | |
| Allergan, INC. | $112.10 | 2019-2020 | |
| Mylan Specialty L.P. | $104.19 | 2019-2024 | Yupelri |
| Amgen INC. | $78.65 | 2022-2023 | Prolia, Evenity |
| United Therapeutics Corporation | $62.46 | 2019-2023 | |
| Harmony Biosciences LLC | $57.01 | 2022-2023 | Wakix |
| Inogen, INC. | $40.95 | 2022-2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Philips North America LLC | $39.57 | 2019-2024 | (8874) Incourage |
| Pfizer INC. | $38.32 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.83 | 2023 | Xifaxan |
| Axsome Therapeutics, INC. | $26.64 | 2023 | Sunosi |
| Ferring Pharmaceuticals INC. | $21.05 | 2023 | Rebyota |
| Baxter Healthcare | $20.88 | 2025 | Hillrom - Monarch Airway Clearance System |
| Janssen Pharmaceuticals, INC | $20.12 | 2022 | |
| Fisher & Paykel Healthcare INC | $18.72 | 2019 | |
| Alnylam Pharmaceuticals INC. | $18.08 | 2023 | Amvuttra |
| Inspire Medical Systems, INC. | $17.14 | 2025 | Inspire |
| Lilly USA, LLC | $17.12 | 2023 | Mounjaro |
| Idorsia Pharmaceuticals US INC | $16.22 | 2023 | Quviviq |
| Novo Nordisk INC | $15.41 | 2023 | Wegovy |
| Lundbeck LLC | $14.71 | 2023 | Rexulti |
| Shield Therapeutics INC | $13.25 | 2023 | Accrufer |
| Takeda Pharmaceuticals U.S.A., INC. | $11.64 | 2021 | |
| Melinta Therapeutics, LLC | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tommy Ko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.